Navigation Links
Nile Therapeutics Receives Notice Related to Nasdaq Minimum Closing Bid Price Rule
Date:6/4/2010

tive products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure, and CU-NP, a novel rationally designed natriuretic peptide. More information on Nile can be found at http://www.nilethera.com.

Safe Harbor Paragraph for Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Nile's ability to regain compliance with Nasdaq's continued listing standards, or the timing, progress and anticipated results of the clinical development, regulatory processes, clinical trial timelines, expected patient enrollment, anticipated benefits of CD-NP, Nile's strategy, future operations, outlook, milestones, the timing and success of Nile's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. Nile may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on Nile's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Nile makes. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that Nile makes include Nile's need to raise additional capital to fund it
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Ascenta Therapeutics Licenses Cancer Drug Candidates to sanofi-aventis
2. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
3. Scientific and Business Leaders to Discuss Challenges Facing Developers of Pain Therapeutics at Arrowhead's 4th Annual Pain Therapeutics Summit
4. Heptares Therapeutics Extends Multi-FTE Chemistry Collaboration With Oxygen Healthcare (O2h)
5. Talecris Biotherapeutics to Present at the 2010 Citi Investment Research Global Health Care Conference
6. Trius Therapeutics Awarded U.S. Department of Defense Contract to Develop Novel Antibiotics
7. Abviva Announces Further Patent Issuance for Technology Used in Breast Cancer Diagnostics and Therapeutics
8. Fate Therapeutics Expands Scientific Advisory Board to Advance iPSC Technology and Stem Cell Modulator Pipeline
9. Nile Therapeutics Announces Exercise of Over-Allotment Option for Recent Public Offering
10. Fate Therapeutics Appoints Tom Novak, Ph.D., as Vice President of Research and Drug Discovery
11. Orexigen(R) Therapeutics to Speak at Ninth Annual JMP Securities Research Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... MESA, Calif. , July 24, 2014  Now ... close to home. Rehealth Regenerative Therapies , located ... athletes and other physically active people a new health ... Regardless of age, countless patients suffer from ... sport activities, such as muscle tears, torn rotator cuff, ...
(Date:7/24/2014)... Security forces worldwide rely on sophisticated equipment, trained ... other public areas against terrorist attacks. A revolutionary ... about to make their job much easier. , ... Patolsky of Tel Aviv University ,s School of ... developed by the Herzliya company Tracense, picks up ...
(Date:7/24/2014)... Distinguished Professor of Engineering at the University of ... solve problems in energy engineering, environmental sustainability and ... zeolites, porous rock with a well-defined, crystalline structure. ... so precisely decided that zeolites can separate molecules ... an angstrom (one-tenth of a nanometer), making them ...
(Date:7/24/2014)... -- Research and Markets has announced the ... Instruments Market 2014-2018" report to their offering. ... is the study of the gene and its functions ... functions of proteomes or sets of proteins by using ... the mapping of genes and DNA sequencing to understand ...
Breaking Biology Technology:Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3Nano-sized chip 'sniffs out' explosives far better than trained dogs 2University of Delaware researcher describes new approach for creating organic zeolites 2Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2
... 15 The Vical Incorporated,(Nasdaq: VICL ) ... on,Monday, September 22, at 1 p.m. Eastern Daylight ... through the Events page at http://www.vical.com ., ... biopharmaceutical products based on its,patented DNA delivery technologies ...
... BioMed Realty Trust, Inc.,(NYSE: BMR ) today announced ... dividend of $0.335 per share of common stock. The,dividend is ... BioMed also announced that its board of directors has ... Series A Cumulative,Redeemable Preferred Stock for the period from July ...
... of Institutional Investors to Attend Conference, MONTREAL, ... ("ProMetic"), today announced that Mr. Pierre Laurin, President,and ... Ford,s 5th,annual Investor Summit on September 16, 2008 ... the Mark Hopkins InterContinental Hotel in San Francisco., ...
Cached Biology Technology:Vical to Present at UBS Global Life Sciences Conference 2BioMed Realty Trust Declares Third Quarter 2008 Common Stock and Preferred Stock Dividends 2ProMetic to present at Merriman Curhan Ford's Investor Summit 2008 on September 16th 2
(Date:7/25/2014)... engineering at the University of Houston, has written ... organ development., "Introduction to Tissue Engineering: Applications and ... the field of artificial organ development. Metin Akay, ... UH, served as a series editor on the ... published books on the subject of growing artificial ...
(Date:7/25/2014)... (NRG1) is a pleiotropic factor characterized by the ... of exons that confer to the protein deeply ... both the myelination occurring during development and the ... nerve: axon degeneration, axon regrowth, remyelination and target ... have discovered that the soluble NRG1 upregulation observed ...
(Date:7/25/2014)... that the age girls reach puberty is influenced by ,imprinted ... parent contributes the gene. This is the first evidence ... birth and details of this study were published today in ... period, known as menarche, is a marker for the timing ... onset of menses varies between girls, is an inherited trait, ...
Breaking Biology News(10 mins):University of Houston researcher publishes textbook on tissue engineering 2Could age of first period influence development of diseases in older women? 2
... Oct. 16, 2012  Today 23andMe, the leading personal ... as Vice President Communications, Neil Rothstein as Vice ... Strategic Alliances joining the company,s executive leadership team. ... Castro is responsible for the company,s corporate communications, ...
... MedNet Solutions, a global life sciences technology solutions ... & Data Corporation (SDC), a specialized Contract Research Organization ... services to the life sciences industry, are pleased to ... ™ EDC platform as their eClinical ...
... MOUNTAIN VIEW, Calif. and RAANANA, Israel, Oct. 23, ... ), the leading licensor of silicon intellectual property ... Ltd, a global supplier of embedded speech processing ... deliver enhanced speech processing solutions for smart devices, ...
Cached Biology News:23andMe Names Christine Castro, Neil Rothstein and Jonathan Ward to Leadership Positions 2Statistics & Data Corporation Selects MedNet Solutions As Strategic Technology Partner 2Statistics & Data Corporation Selects MedNet Solutions As Strategic Technology Partner 3CEVA, Rubidium Partner to Deliver Speech Processing Solutions based on the CEVA-TeakLite Family of DSPs 2CEVA, Rubidium Partner to Deliver Speech Processing Solutions based on the CEVA-TeakLite Family of DSPs 3
... Proteolytic degradation is critical to the ... and regulatory proteins as important and ... metabolism, heat shock and stress response, ... receptors and ion channels, cell cycle ...
... scanner serves as the spot-picking platform. This ... rack positions on the tray, leaving space ... on the remaining two racks.,The software allows ... mouse-click on the scanned gel image. The ...
...
... configured specifically for pharmaceutical powder packaging, ... are precision-joined to create ultra-smooth surfaces ... and disinfect. One-inch radius corners simplify ... strong, rigid surface without external bracing. ...
Biology Products: